Shares of Telesis Bio, Inc. (NASDAQ: TBIO) are soaring on the US stock charts today, following the announcement of a significant partnership. In pre-market trading, TBIO stock surged 105.60% as of the latest check, reaching a value of $4.77. This rise reflects the market’s positive response to the new collaboration between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation.
Telesis Partnered to Drive Scalable Biofoundries
The collaboration between Telesis Bio and Beckman Coulter Life Sciences aims to develop highly efficient and scalable biofoundries. These biofoundries will facilitate sustainable and rapid on-premises DNA synthesis using Telesis Bio’s Gibson SOLA enzymatic reagent platform.
Combining this cutting-edge platform with the automated technology of Beckman Coulter allows for the scalable, dependable, and quick manufacture of high-fidelity DNA. It is anticipated that the collaboration would greatly improve researchers’ capacity to make breakthroughs in a variety of discovery applications.
TBIO On Path To Flexibility And Innovation In Synthetic Biology
A key aspect of the collaboration is the integration of Gibson SOLA Enzymatic Synthesis with Beckman Coulter’s Biomek Echo One System, an advanced automation tool. This integration offers an open and flexible solution, allowing researchers to incorporate constructs from other providers compatible with Gibson SOLA technology.
This capability enhances the technology’s flexibility and broadens its applications in synthesizing unique and complex biological structures. Telesis Bio’s partnership is poised to revolutionize synthetic biology, enabling the creation of local DNA foundries that function as digital-to-biologic converters. These biofoundries can deliver DNA or mRNA at an unprecedented speed, potentially as fast as overnight.
Advancing Therapeutic And Diagnostic Discoveries
For Beckman Coulter, this collaboration aligns with its mission to be a trusted laboratory partner by facilitating breakthrough research through more efficient and accurate processes. The Biomek Echo One System streamlines critical workflows such as DNA extraction, fragmentation, and ligation, bringing new levels of automation to DNA and mRNA synthesis.
This partnership represents a pivotal moment in the advancement of synthetic biology, setting a new standard for on-premises biofoundries and fostering the next wave of therapeutic and diagnostic innovations.
